Drug interactions
Empagliflozin-linagliptin + Rucaparib
Severity: Minor
Empagliflozin-linagliptin and Rucaparib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Rucaparib is a weak inhibitor of CYP3A4 and may slightly increase linagliptin concentrations. The change is unlikely to be clinically important given linagliptin's safety margin.
What this interaction means in plain words
Empagliflozin-linagliptin and Rucaparib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Empagliflozin-linagliptin belongs to Endocrine; Rucaparib belongs to Oncology.
Why it happens
Weak CYP3A4 inhibition by rucaparib reduces linagliptin metabolism.
What to do
No dose adjustment is generally required. Monitor glucose and watch for hypoglycemia if other antidiabetics are used.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Empagliflozin-linagliptin and Rucaparib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Empagliflozin-linagliptin
Other interactions of Rucaparib
- Cisapride + Rucaparib Major
- Ergotamine + Rucaparib Major
- Pimozide + Rucaparib Major
- Alfuzosin + Rucaparib Moderate
- Aripiprazole + Rucaparib Moderate
- Atorvastatin + Rucaparib Moderate
Frequently asked questions
Can I take Empagliflozin-linagliptin with Rucaparib?
MediHelp rates the interaction as minor. Empagliflozin-linagliptin and Rucaparib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Rucaparib is a weak inhibitor of CYP3A4 and may slightly increase linagliptin concentrations. The change is unlikely to be clinically important given linagliptin's safety margin.
How serious is the interaction between Empagliflozin-linagliptin and Rucaparib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose adjustment is generally required. Monitor glucose and watch for hypoglycemia if other antidiabetics are used.
What other medicines interact with Empagliflozin-linagliptin?
MediHelp also lists interactions of Empagliflozin-linagliptin with, for example, Fosphenytoin, Rifampin, Rifapentine. The full list is on the Empagliflozin-linagliptin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
